Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® – – First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 – – Work restrictions at the NCI and MD Anderson easing; MD Anderson initiated phase 1 CD19-specific CAR-T
View HTML
Toggle Summary Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020
BOSTON , July 28, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020 .
View HTML
Toggle Summary Ziopharm Oncology Names James Huang to Board of Directors
– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech   – Managing Partner at Kleiner Perkins Caufield & China; Founder of Panacea Venture, funding source for Ziopharm’s joint venture
View HTML
Toggle Summary Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas
- RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer - BOSTON , July 09, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced the initiation of a phase
View HTML
Toggle Summary Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors
BOSTON , July 08, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the
View HTML
Toggle Summary Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma
BOSTON , June 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with the PD-1 inhibitor Libtayo
View HTML
Toggle Summary Ziopharm Oncology Appoints Carl June, M.D., as Chairman of Scientific Advisory Board
BOSTON , June 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of renowned oncology and immunotherapy pioneer, Carl June , M.D., as Chairman of its newly formed Scientific Advisory Board (SAB). Dr.
View HTML
Toggle Summary Ziopharm Oncology to Participate in Cell Therapy Panel at the Raymond James Human Healthcare Innovation Conference on June 17, 2020
BOSTON , June 12, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a webcast panel session titled Cell Therapy : Promise of the Next Generation at the Raymond
View HTML
Toggle Summary Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology
  – Longer term follow-up from Controlled IL-12 monotherapy studies reinforces encouraging median overall survival and favorable safety profile –   – Controlled IL-12 in combination with PD-1 inhibitor has favorable safety profile and initial survival data are encouraging – – Data again consistent
View HTML
Toggle Summary Ziopharm Oncology Announces Management Transition
Dr. David Mauney stepping down as President; Remains a consultant to the Company BOSTON , May 27, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced Dr. David Mauney is stepping down as President. Dr.
View HTML